Twitter | Pretraživanje | |
STAT
Opinion: There are few things in this world more squishy than Wonder Bread. Exception: Biogen’s answers to the question of when it will submit aducanumab to the FDA.
17:00 - 2. velj 2020.
As Biogen gets squishy on timing for aducanumab filing, the clock is ticking
Baird analyst Brian Skorney says Biogen deserves criticism for its evasiveness on the issue of when it will submit its Alzheimer's drug to the FDA.
STAT STAT @statnews
Reply Retweet Označi sa "sviđa mi se" More
HealthCarer 3. velj
Odgovor korisniku/ci @statnews
Presumably when they have tortured the data some more and it squeals a suggestion of therapeutic efficacy?
Prikaz razgovora · Reply Retweet Označi sa "sviđa mi se"